Display options
Cite
van Gysen K, Kneebone A, Eade T, et al. Advanced Renal Cell Cancer and Low-Dose Palliative Radiation Treatment: A Case of a Substantial and Sustained Treatment Response. Case Rep Oncol. 2018;11(3):756-762doi: 10.1159/000493913.
van Gysen, K., Kneebone, A., Eade, T., Guminski, A., & Hruby, G. (2018). Advanced Renal Cell Cancer and Low-Dose Palliative Radiation Treatment: A Case of a Substantial and Sustained Treatment Response. Case reports in oncology, 11(3), 756-762. https://doi.org/10.1159/000493913
van Gysen, Kirsten, et al. "Advanced Renal Cell Cancer and Low-Dose Palliative Radiation Treatment: A Case of a Substantial and Sustained Treatment Response." Case reports in oncology vol. 11,3 (2018): 756-762. doi: https://doi.org/10.1159/000493913
van Gysen K, Kneebone A, Eade T, Guminski A, Hruby G. Advanced Renal Cell Cancer and Low-Dose Palliative Radiation Treatment: A Case of a Substantial and Sustained Treatment Response. Case Rep Oncol. 2018 Nov 27;11(3):756-762. doi: 10.1159/000493913. eCollection 2018. PMID: 30627089; PMCID: PMC6323401.
Copy Download .nbib Format: NLM
Share it on

Case Rep Oncol. 2018 Nov 27;11(3):756-762. doi: 10.1159/000493913. eCollection 2018.

Advanced Renal Cell Cancer and Low-Dose Palliative Radiation Treatment: A Case of a Substantial and Sustained Treatment Response.

Case reports in oncology

Kirsten van Gysen, Andrew Kneebone, Thomas Eade, Alexander Guminski, George Hruby

Affiliations

  1. Northern Sydney Cancer Centre, Royal North Shore Hospital, Sydney, New South Wales, Australia.
  2. Northern Clinical School, University of Sydney, Sydney, New South Wales, Australia.

PMID: 30627089 PMCID: PMC6323401 DOI: 10.1159/000493913

Abstract

Clear cell carcinoma is the most common form of renal cell carcinoma (RCC). Metastatic RCC is poorly responsive to treatment and has a bleak prognosis. Newer systemic agents have improved outcomes. Furthermore, their interaction with radiation treatment (RT) may provide further therapeutic options. RCC is considered to be radioresistant, however we report the case of a patient with progression on targeted therapy and immunotherapy who achieved a substantial and sustained local, and possibly abscopal, response to low dose palliative radiation therapy.

Keywords: Immunotherapy; Radiation therapy; Renal cell carcinoma; Targeted therapy

References

  1. Int J Radiat Oncol Biol Phys. 1996 Jan 1;34(1):251-66 - PubMed
  2. Cancer Cell. 2005 Aug;8(2):99-110 - PubMed
  3. Lancet Oncol. 2009 Jul;10(7):718-26 - PubMed
  4. Radiat Res. 2009 May;171(5):606-14 - PubMed
  5. Lancet. 2011 Dec 3;378(9807):1931-9 - PubMed
  6. Radiother Oncol. 2014 Apr;111(1):88-93 - PubMed
  7. Cancer Treat Rev. 2015 Jun;41(6):503-10 - PubMed
  8. N Engl J Med. 2015 Nov 5;373(19):1803-13 - PubMed
  9. Lancet Oncol. 2018 Mar;19(3):405-415 - PubMed

Publication Types